Guggul: the resin that reached a pharmaceutical trial and did not survive it

Guggul is the oleoresin of Commiphora wightii, used extensively in classical Ayurveda, particularly in formulations for joint conditions and for what the texts describe as conditions of accumulation.

In the twentieth century it attracted attention as a lipid-lowering agent, and its subsequent history is instructive.

The early findings

Research in India from the 1960s onward reported lipid-lowering effects, and a standardised extract was developed and marketed as a treatment for elevated cholesterol.

Several studies, mostly conducted in India, reported reductions in total and LDL cholesterol. The preparation became widely used and was subsequently marketed internationally as a natural cholesterol treatment.

The trial that changed the picture

A randomised, double-blind, placebo-controlled trial conducted in the United States and published in a major medical journal examined a standardised guggul extract in adults with elevated cholesterol.

The result was that LDL cholesterol increased in the treatment groups relative to placebo. The trial also reported a hypersensitivity rash in a proportion of participants.

This was not the expected finding, and it prompted reassessment.

Explanations offered for the discrepancy with earlier work include differences in the populations studied — the earlier studies were largely in Indian populations with different baseline diets — differences in the extracts used, and methodological limitations in the earlier trials.

Subsequent reviews have generally concluded that the evidence does not support guggul for lipid lowering, and that findings are inconsistent.

Why this case is worth understanding

It illustrates several things at once.

Early positive findings frequently do not survive rigorous testing. This is true across all of medicine, not only for traditional preparations. A substantial proportion of promising early results fail to replicate.

Population matters. A result obtained in one population with one background diet may not transfer.

Extract standardisation matters. Different preparations of the same plant are different interventions.

Doing the trial is the only way to know. The traditional use, the mechanistic rationale and the early studies all pointed one way, and a well-designed trial pointed another.

That is exactly what proper testing is for, and the fact that a traditional preparation was subjected to it is a good thing rather than an attack on the tradition.

Other applications

Osteoarthritis. Some trials of guggul preparations report reductions in pain and stiffness. Studies are small and quality is limited. This is the application with the more plausible remaining case.

Weight and metabolic parameters. Limited and inconsistent evidence.

Acne. A small number of older studies, insufficient to draw conclusions.

Safety

Thyroid effects. Guggul has been reported to affect thyroid function. Relevant for anyone with thyroid disease or on thyroid medication.

Hypersensitivity. Rash was reported in a proportion of participants in the trial described above, and this is a documented adverse effect.

Gastrointestinal effects, commonly reported.

Drug interactions. Guggul affects drug-metabolising enzymes and has been reported to reduce levels of some medications, including propranolol and diltiazem in one study. This is a genuine interaction concern.

Bleeding risk, with possible antiplatelet activity.

Pregnancy. Traditionally contraindicated and should be avoided.

Conservation. Worth noting: Commiphora wightii is assessed as threatened in the wild due to over-harvesting, which is a consideration in sourcing and a broader issue affecting several medicinal plants.

What to do about cholesterol instead

Since this is the application guggul is most marketed for, the alternatives are worth stating.

Statins have among the most extensive evidence bases in all of medicine, with large trials demonstrating reductions in cardiovascular events and mortality. The debate about them in popular media does not reflect the state of the evidence.

Dietary change with evidence includes replacing saturated with unsaturated fat, increasing soluble fibre, and plant stanols and sterols, which have a genuine modest effect.

Physical activity, weight management where relevant, and smoking cessation all contribute.

Anyone with elevated cholesterol should have their overall cardiovascular risk assessed rather than focusing on the number alone, since treatment decisions depend on total risk.

Do not use herbal preparations in place of prescribed lipid-lowering treatment. Discuss any supplement with your doctor, particularly if you have thyroid disease or take cardiovascular medication.